NSCI — Nanalysis Scientific Share Price
0.000.00%
Last trade - 00:00- CA$50.27m
- CA$71.48m
- CA$28.47m
- 31
- 43
- 53
- 38
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 2.14 | ||
| Price to Tang. Book | 27.34 | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | 1.77 | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | -33.89% | ||
| Return on Equity | -55.27% | ||
| Operating Margin | -46.7% | ||
Financial Summary
| Year End 31st Dec | Unit | 2019 | 2020 | 2021 | 2022 | 2023 | 2024E | 2025E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | CA$m | 8.36 | 7.87 | 16.04 | 24.82 | 28.47 | 34.1 | n/a | 27.71% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Nanalysis Scientific Corp. is a Canada-based patent-protected technology company that develops, manufactures and sells magnetic resonance (MR) products for security, pharmaceutical, biotech, nutraceutical, chemical, food, materials, education, life science and medical applications. The Company operates through four segments: Nanalysis, RS2D, K’Prime and Corporate. The Company’s subsidiaries include Nanalysis Corp., Nanalysis GmbH, RS2D S.A.S., One Moon Scientific (OMS), K'(Prime) Technologies Inc., KPrime Group USA, KPrime Technologies, Quad Systems AG and Quad Systems Ltd. RS2D S.A.S. is a technology company that is specialized in the designing of compact, electronics components for a range of precision analytical MR instruments, including both NMR and magnetic resonance imaging (MRI). OMS is a software company, which is specialized in a suite of software tools to streamline and automate magnetic resonance data analysis and management.
Directors
- Sean Krakiwsky PRE
- Luke Caplette CFO
- Julien Mueller CTO
- Garett Leskowitz CSO
- Susanne Riegel DMK
- Neal Gallagher OTH
- Bruce Lix OTH
- Greg Mcfeetors OTH
- Heather Phillips OTH
- Matt Zamora OTH
- Martin Burian IND
- Guido Cloetens IND
- Werner Gartner IND (63)
- Michal Okoniewski IND
- Last Annual
- December 31st, 2023
- Last Interim
- December 31st, 2023
- Incorporated
- February 27th, 2017
- Public Since
- June 29th, 2017
- No. of Employees
- 130
- Sector
- Healthcare Equipment & Supplies
- Industry
- Healthcare
- Exchange
- TSX Venture Exchange
- Shares in Issue
- 111,721,681
- Address
- Bay 1, 4600-5 Street NE, CALGARY, T2E 7C3
- Web
- https://www.nanalysis.com/nsci-overview
- Phone
- +1 4037699499
- Contact
- Matthew Selinger
- Auditors
- Ernst & Young LLP
Upcoming Events for NSCI
Nanalysis Scientific Corp. Annual Shareholders Meeting
Q2 2024 Nanalysis Scientific Corp. Earnings Release
Similar to NSCI
Aurora Spine
TSX Venture Exchange
CardioComm Solutions
TSX Venture Exchange
Cloud DX
TSX Venture Exchange
Enablence Technologies
TSX Venture Exchange
EvokAI Creative Labs
TSX Venture Exchange
FAQ
What is the Nanalysis Scientific share price?
As of Today at 19:15 UTC, shares in Nanalysis Scientific are trading at CA$0.45. This share price information is delayed by 15 minutes.
How has the Nanalysis Scientific share price performed this year?
Shares in Nanalysis Scientific last closed at CA$0.45 and the price had moved by -11.76% over the past 365 days. In terms of relative price strength the Nanalysis Scientific share price has underperformed the Toronto Stock Exchange 300 Composite Index by -20.07% over the past year.
What are the analyst and broker recommendations for Nanalysis Scientific?
The overall consensus recommendation for Nanalysis Scientific is Buy. You can view the full broker recommendation list by unlocking its StockReport.
What is the Nanalysis Scientific dividend yield?
Nanalysis Scientific does not currently pay a dividend.
Does Nanalysis Scientific pay a dividend?
Nanalysis Scientific does not currently pay a dividend.
When does Nanalysis Scientific next pay dividends?
Nanalysis Scientific does not currently pay a dividend.
How do I buy Nanalysis Scientific shares?
To buy shares in Nanalysis Scientific you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
What is the market cap of Nanalysis Scientific?
As of the previous close price of CA$0.45, shares in Nanalysis Scientific had a market capitalisation of CA$50.27m.
Where are Nanalysis Scientific shares listed?
Here are the trading details for Nanalysis Scientific:
- Country of listing: Canada
- Exchange: CVE
- Ticker Symbol: NSCI
What kind of share is Nanalysis Scientific?
Based on an overall assessment of its quality, value and momentum Nanalysis Scientific is currently classified as a Neutral. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
Is there a Nanalysis Scientific share price forecast for 2024?
The analyst consensus target price for shares in Nanalysis Scientific is CA$1.20. That is 166.67% above the last closing price of CA$0.45.
Analysts covering Nanalysis Scientific currently have a consensus Earnings Per Share (EPS) forecast of -CA$0.06 for the next financial year.
What is the trend in the Nanalysis Scientific share price?
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Nanalysis Scientific. Over the past six months, its share price has underperformed the Toronto Stock Exchange 300 Composite Index by -7.83%.
As of the last closing price of CA$0.45, shares in Nanalysis Scientific were trading -1.59% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
What is the Nanalysis Scientific PE Ratio?
The Nanalysis Scientific PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at CA$0.45.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Who are the key directors of Nanalysis Scientific?
Nanalysis Scientific's management team is headed by:
- Sean Krakiwsky - PRE
- Luke Caplette - CFO
- Julien Mueller - CTO
- Garett Leskowitz - CSO
- Susanne Riegel - DMK
- Neal Gallagher - OTH
- Bruce Lix - OTH
- Greg Mcfeetors - OTH
- Heather Phillips - OTH
- Matt Zamora - OTH
- Martin Burian - IND
- Guido Cloetens - IND
- Werner Gartner - IND
- Michal Okoniewski - IND